PMID- 32603400
OWN - NLM
STAT- MEDLINE
DCOM- 20210422
LR  - 20210422
IS  - 2326-6929 (Electronic)
IS  - 0011-4162 (Linking)
VI  - 105
IP  - 5
DP  - 2020 May
TI  - Topical clobetasol propionate treatment and cutaneous adverse effects in patients 
      with early-stage mycosis fungoides: an observational study.
PG  - E27-E32
AB  - Topical superpotent class I corticosteroids (CSs) are highly effective in the 
      treatment of early-stage mycosis fungoides (MF) and are readily available, easily 
      applied, and have minor side effects compared to other topical therapeutic 
      options. Because MF is a chronic disease, prolonged treatment is needed, raising 
      the concern of CS-induced cutaneous adverse effects (AEs). In this observational 
      study, we aimed to evaluate the risk for skin AEs of clobetasol propionate cream 
      0.05% in patients with early-stage MF. Thirteen consecutive patients with MF were 
      treated with clobetasol propionate cream 0.05% once or twice daily as monotherapy 
      and were followed for 4 to 17 months. One participant was lost to follow-up, and 
      the remaining 12 participants responded to treatment with topical clobetasol 
      propionate with minimal side effects. With proper education and monitoring, 
      topical CSs are a safe and effective mainstay of treatment for patches and flat 
      plaques in patients with early-stage localized MF.
FAU - Geller, Shamir
AU  - Geller S
AD  - Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer 
      Center, New York, New York, USA; and Division of Dermatology, Tel Aviv Sourasky 
      Medical Center, Sackler Faculty of Medicine, Israel.
FAU - Myskowski, Patricia L
AU  - Myskowski PL
AD  - Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer 
      Center, New York, New York; and Weill Cornell Medicine, USA.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Cutis
JT  - Cutis
JID - 0006440
RN  - 0 (Glucocorticoids)
RN  - ADN79D536H (Clobetasol)
SB  - IM
MH  - Administration, Topical
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrophy/chemically induced
MH  - Clobetasol/*administration & dosage/adverse effects
MH  - Female
MH  - Glucocorticoids/*administration & dosage/adverse effects
MH  - Humans
MH  - Hypopigmentation/chemically induced
MH  - Male
MH  - Middle Aged
MH  - Mycosis Fungoides/*drug therapy
MH  - Prospective Studies
MH  - Skin/drug effects/pathology
MH  - Skin Cream/administration & dosage/adverse effects
MH  - Skin Neoplasms/*drug therapy
EDAT- 2020/07/01 06:00
MHDA- 2021/04/23 06:00
CRDT- 2020/07/01 06:00
PHST- 2020/07/01 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/04/23 06:00 [medline]
PST - ppublish
SO  - Cutis. 2020 May;105(5):E27-E32.